Futura Medical plc Logo

Futura Medical plc

FUM.L

(0.5)
Stock Price

36,40 GBp

-90.33% ROA

-80.21% ROE

-16.12x PER

Market Cap.

106.846.617,00 GBp

0% DER

0% Yield

-299.73% NPM

Futura Medical plc Stock Analysis

Futura Medical plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Futura Medical plc Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

2 ROE

Negative ROE (-80.95%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (-90.33%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

4 PBV

The stock's elevated P/BV ratio (18.67x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Futura Medical plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Futura Medical plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Futura Medical plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Futura Medical plc Revenue
Year Revenue Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 130.000 100%
2005 2.000 -6400%
2006 0 0%
2007 15.000 100%
2008 150.000 90%
2009 50.000 -200%
2010 125.000 60%
2011 158.000 20.89%
2012 75.000 -110.67%
2013 370.902 79.78%
2014 43.929 -744.32%
2015 29.476 -49.03%
2016 170.362 82.7%
2017 362.727 53.03%
2018 0 0%
2019 31.778 100%
2020 0 0%
2021 0 0%
2022 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Futura Medical plc Research and Development Expenses
Year Research and Development Expenses Growth
2000 207.000
2001 683.000 69.69%
2002 811.000 15.78%
2003 627.000 -29.35%
2004 960.000 34.69%
2005 1.553.000 38.18%
2006 1.080.000 -43.8%
2007 1.520.000 28.95%
2008 1.398.000 -8.73%
2009 810.000 -72.59%
2010 762.000 -6.3%
2011 1.000 -76100%
2012 1.435.731 99.93%
2013 1.976.322 27.35%
2014 2.365.678 16.46%
2015 4.778.039 50.49%
2016 3.509.680 -36.14%
2017 4.100.453 14.41%
2018 6.038.941 32.1%
2019 10.051.148 39.92%
2020 1.927.658 -421.42%
2021 3.774.269 48.93%
2022 4.131.224 8.64%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Futura Medical plc General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 711.000 100%
2005 721.000 1.39%
2006 935.000 22.89%
2007 1.122.000 16.67%
2008 910.000 -23.3%
2009 721.000 -26.21%
2010 632.000 -14.08%
2011 2.191.000 71.15%
2012 1.095.197 -100.06%
2013 926.123 -18.26%
2014 1.205.078 23.15%
2015 1.368.240 11.92%
2016 1.214.755 -12.64%
2017 1.118.218 -8.63%
2018 1.227.547 8.91%
2019 1.144.397 -7.27%
2020 1.000.736 -14.36%
2021 2.092.042 52.16%
2022 2.740.265 23.66%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Futura Medical plc EBITDA
Year EBITDA Growth
2000 -385.000
2001 -1.312.000 70.66%
2002 -1.222.000 -7.36%
2003 -1.447.000 15.55%
2004 -1.379.000 -4.93%
2005 -2.210.000 37.6%
2006 -1.962.000 -12.64%
2007 -2.448.000 19.85%
2008 -2.062.000 -18.72%
2009 -1.501.000 -37.38%
2010 -1.309.000 -14.67%
2011 -2.071.000 36.79%
2012 -2.453.746 15.6%
2013 -2.527.760 2.93%
2014 -3.522.300 28.24%
2015 -6.109.845 42.35%
2016 -4.547.826 -34.35%
2017 -4.842.516 6.09%
2018 -7.246.638 33.18%
2019 -11.120.780 34.84%
2020 -2.903.386 -283.03%
2021 -5.846.503 50.34%
2022 -6.846.755 14.61%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Futura Medical plc Gross Profit
Year Gross Profit Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 130.000 100%
2005 2.000 -6400%
2006 0 0%
2007 15.000 100%
2008 150.000 90%
2009 50.000 -200%
2010 125.000 60%
2011 158.000 20.89%
2012 75.000 -110.67%
2013 370.902 79.78%
2014 43.929 -744.32%
2015 29.476 -49.03%
2016 170.362 82.7%
2017 362.727 53.03%
2018 0 0%
2019 31.778 100%
2020 0 0%
2021 0 0%
2022 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Futura Medical plc Net Profit
Year Net Profit Growth
2000 -372.000
2001 -1.250.000 70.24%
2002 -1.085.000 -15.21%
2003 -1.360.000 20.22%
2004 -1.229.000 -10.66%
2005 -1.936.000 36.52%
2006 -1.777.000 -8.95%
2007 -2.254.000 21.16%
2008 -1.935.000 -16.49%
2009 -1.393.000 -38.91%
2010 -1.091.000 -27.68%
2011 -1.815.000 39.89%
2012 -2.176.649 16.61%
2013 -2.208.332 1.43%
2014 -2.997.881 26.34%
2015 -5.081.442 41%
2016 -3.697.113 -37.44%
2017 -3.900.284 5.21%
2018 -5.880.576 33.68%
2019 -8.919.290 34.07%
2020 -2.408.377 -270.34%
2021 -4.957.711 51.42%
2022 -5.846.495 15.2%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Futura Medical plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Futura Medical plc Free Cashflow
Year Free Cashflow Growth
2000 -318.000
2001 -1.334.000 76.16%
2002 -1.065.000 -25.26%
2003 -1.359.000 21.63%
2004 -1.472.000 7.68%
2005 -2.139.000 31.18%
2006 -1.857.000 -15.19%
2007 -2.313.000 19.71%
2008 -1.973.000 -17.23%
2009 -1.319.000 -49.58%
2010 -1.053.000 -25.26%
2011 -1.836.000 42.65%
2012 -1.945.054 5.61%
2013 -2.019.006 3.66%
2014 -3.074.519 34.33%
2015 -5.379.808 42.85%
2016 -3.305.477 -62.75%
2017 -4.230.401 21.86%
2018 -4.712.545 10.23%
2019 -1.672.246 -181.81%
2020 -4.551.726 63.26%
2021 -4.292.992 -6.03%
2022 -6.516.043 34.12%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Futura Medical plc Operating Cashflow
Year Operating Cashflow Growth
2000 -316.000
2001 -1.284.000 75.39%
2002 -1.062.000 -20.9%
2003 -1.357.000 21.74%
2004 -1.451.000 6.48%
2005 -2.125.000 31.72%
2006 -1.852.000 -14.74%
2007 -2.282.000 18.84%
2008 -1.971.000 -15.78%
2009 -1.318.000 -49.54%
2010 -1.047.000 -25.88%
2011 -1.836.000 42.97%
2012 -1.940.808 5.4%
2013 -2.013.958 3.63%
2014 -3.066.726 34.33%
2015 -5.363.850 42.83%
2016 -3.297.994 -62.64%
2017 -4.174.807 21%
2018 -4.708.035 11.33%
2019 -1.664.062 -182.92%
2020 -4.543.355 63.37%
2021 -3.873.270 -17.3%
2022 -5.775.346 32.93%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Futura Medical plc Capital Expenditure
Year Capital Expenditure Growth
2000 2.000
2001 50.000 96%
2002 3.000 -1566.67%
2003 2.000 -50%
2004 21.000 90.48%
2005 14.000 -50%
2006 5.000 -180%
2007 31.000 83.87%
2008 2.000 -1450%
2009 1.000 -100%
2010 6.000 83.33%
2011 0 0%
2012 4.246 100%
2013 5.048 15.89%
2014 7.793 35.22%
2015 15.958 51.17%
2016 7.483 -113.26%
2017 55.594 86.54%
2018 4.510 -1132.68%
2019 8.184 44.89%
2020 8.371 2.23%
2021 419.722 98.01%
2022 740.697 43.33%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Futura Medical plc Equity
Year Equity Growth
2000 -294.000
2001 1.999.000 114.71%
2002 1.519.000 -31.6%
2003 2.409.000 36.94%
2004 3.748.000 35.73%
2005 1.980.000 -89.29%
2006 3.948.000 49.85%
2007 2.773.000 -42.37%
2008 886.000 -212.98%
2009 1.853.000 52.19%
2010 901.000 -105.66%
2011 2.758.000 67.33%
2012 2.873.276 4.01%
2013 987.772 -190.88%
2014 9.721.811 89.84%
2015 4.786.231 -103.12%
2016 12.584.028 61.97%
2017 9.105.758 -38.2%
2018 8.852.254 -2.86%
2019 53.652 -16399.39%
2020 853.540 93.71%
2021 9.724.612 91.22%
2022 4.719.553 -106.05%
2023 8.012.214 41.1%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Futura Medical plc Assets
Year Assets Growth
2000 336.000
2001 2.261.000 85.14%
2002 1.766.000 -28.03%
2003 2.589.000 31.79%
2004 3.973.000 34.84%
2005 2.217.000 -79.21%
2006 4.184.000 47.01%
2007 3.088.000 -35.49%
2008 1.038.000 -197.5%
2009 2.077.000 50.02%
2010 1.053.000 -97.25%
2011 2.952.000 64.33%
2012 3.208.229 7.99%
2013 1.465.770 -118.88%
2014 10.329.697 85.81%
2015 5.515.349 -87.29%
2016 13.439.205 58.96%
2017 9.604.899 -39.92%
2018 10.877.769 11.7%
2019 4.901.172 -121.94%
2020 1.620.065 -202.53%
2021 11.802.796 86.27%
2022 6.472.662 -82.35%
2023 10.207.540 36.59%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Futura Medical plc Liabilities
Year Liabilities Growth
2000 630.000
2001 262.000 -140.46%
2002 247.000 -6.07%
2003 180.000 -37.22%
2004 225.000 20%
2005 237.000 5.06%
2006 236.000 -0.42%
2007 315.000 25.08%
2008 152.000 -107.24%
2009 224.000 32.14%
2010 152.000 -47.37%
2011 194.000 21.65%
2012 334.953 42.08%
2013 477.998 29.93%
2014 607.886 21.37%
2015 729.118 16.63%
2016 855.177 14.74%
2017 499.141 -71.33%
2018 2.025.515 75.36%
2019 4.847.520 58.22%
2020 766.525 -532.4%
2021 2.078.184 63.12%
2022 1.753.109 -18.54%
2023 2.195.326 20.14%

Futura Medical plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.02
Price to Earning Ratio
-16.12x
Price To Sales Ratio
0x
POCF Ratio
-16.32
PFCF Ratio
-16.4
Price to Book Ratio
19.97
EV to Sales
0
EV Over EBITDA
-15.02
EV to Operating CashFlow
-17.8
EV to FreeCashFlow
-15.78
Earnings Yield
-0.06
FreeCashFlow Yield
-0.06
Market Cap
0,11 Bil.
Enterprise Value
0,10 Bil.
Graham Number
0.09
Graham NetNet
0.01

Income Statement Metrics

Net Income per Share
-0.02
Income Quality
0.84
ROE
-0.81
Return On Assets
-0.5
Return On Capital Employed
-0.75
Net Income per EBT
0.85
EBT Per Ebit
1
Ebit per Revenue
-3.51
Effective Tax Rate
0.15

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.49
Operating Profit Margin
-3.51
Pretax Profit Margin
-3.51
Net Profit Margin
-3

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.02
Free CashFlow per Share
-0.02
Capex to Operating CashFlow
0.13
Capex to Revenue
0
Capex to Depreciation
-29.95
Return on Invested Capital
-1.24
Return on Tangible Assets
-0.9
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
-0

Balance Sheet

Cash per Share
0,01
Book Value per Share
0,02
Tangible Book Value per Share
0.02
Shareholders Equity per Share
0.02
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.59
Current Ratio
3.03
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Futura Medical plc Dividends
Year Dividends Growth

Futura Medical plc Profile

About Futura Medical plc

Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.

CEO
Mr. James Henry Barder
Employee
12
Address
Surrey Technology Centre
Guildford, GU2 7YG

Futura Medical plc Executives & BODs

Futura Medical plc Executives & BODs
# Name Age
1 Graham Smith
Head of Alliance Partnerships & Supply
70
2 Kevin Langridge
Head of Quality
70
3 Ms. Angela Hildreth
Chief Operating Officer, Finance Director, Company Secretary & Executive Director
70
4 Dr. William Duncan Potter
Chief Scientific Officer & Adviser to the Board
70
5 Mr. Kenneth William James
Head of R&D & Executive Director
70
6 Mr. James Henry Barder
Chief Executive Officer & Executive Director
70

Futura Medical plc Competitors

ImmuPharma plc Logo
ImmuPharma plc

IMM.L

(0.8)
genedrive plc Logo
genedrive plc

GDR.L

(0.8)
Avacta Group Plc Logo
Avacta Group Plc

AVCT.L

(0.0)
Scancell Holdings plc Logo
Scancell Holdings plc

SCLP.L

(1.0)
Synairgen plc Logo
Synairgen plc

SNG.L

(1.0)